KR20090065524A - 프로그래머블 부력전달기술 - Google Patents

프로그래머블 부력전달기술 Download PDF

Info

Publication number
KR20090065524A
KR20090065524A KR1020097006969A KR20097006969A KR20090065524A KR 20090065524 A KR20090065524 A KR 20090065524A KR 1020097006969 A KR1020097006969 A KR 1020097006969A KR 20097006969 A KR20097006969 A KR 20097006969A KR 20090065524 A KR20090065524 A KR 20090065524A
Authority
KR
South Korea
Prior art keywords
active agent
core
layer
agents
polymerization
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020097006969A
Other languages
English (en)
Korean (ko)
Inventor
아말지트 싱
사라브지트 싱
쉬바난드 푸쓰리
라존드라 탄다레
Original Assignee
파나세아 바이오테크 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 파나세아 바이오테크 리미티드 filed Critical 파나세아 바이오테크 리미티드
Publication of KR20090065524A publication Critical patent/KR20090065524A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Inorganic Chemistry (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020097006969A 2006-09-04 2007-09-03 프로그래머블 부력전달기술 Ceased KR20090065524A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN1411/MUM/2006 2006-09-04
IN1411MU2006 2006-09-04

Publications (1)

Publication Number Publication Date
KR20090065524A true KR20090065524A (ko) 2009-06-22

Family

ID=39430167

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020097006969A Ceased KR20090065524A (ko) 2006-09-04 2007-09-03 프로그래머블 부력전달기술

Country Status (16)

Country Link
US (1) US8277843B2 (cg-RX-API-DMAC7.html)
EP (1) EP2068844A4 (cg-RX-API-DMAC7.html)
JP (1) JP2010502591A (cg-RX-API-DMAC7.html)
KR (1) KR20090065524A (cg-RX-API-DMAC7.html)
CN (1) CN101511346B (cg-RX-API-DMAC7.html)
AR (1) AR062644A1 (cg-RX-API-DMAC7.html)
AU (1) AU2007323018B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0716481A2 (cg-RX-API-DMAC7.html)
CA (1) CA2661172A1 (cg-RX-API-DMAC7.html)
CL (1) CL2007002562A1 (cg-RX-API-DMAC7.html)
IL (1) IL197121A0 (cg-RX-API-DMAC7.html)
MX (1) MX2009002371A (cg-RX-API-DMAC7.html)
NO (1) NO20090807A (cg-RX-API-DMAC7.html)
RU (1) RU2420268C2 (cg-RX-API-DMAC7.html)
WO (1) WO2008062440A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA200901162B (cg-RX-API-DMAC7.html)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7201920B2 (en) 2003-11-26 2007-04-10 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of opioid containing dosage forms
ZA200903858B (en) * 2008-06-19 2013-10-30 Univ Of Witwatesrand Johannesburg Pharmaceutical dosage form
WO2009153635A1 (en) * 2008-06-19 2009-12-23 University Of Witwatersrand, Johannesburg A chronotherapeutic pharmaceutical dosage form
CA2638240C (en) * 2008-08-29 2010-02-02 Alexander Macgregor Method of treating dysglycemia and glucose excursions
CA2767143A1 (en) * 2009-07-06 2011-01-13 Kyorin Pharmaceutical Co., Ltd. Tablet having hollow structure
EP3064064A1 (en) 2009-09-30 2016-09-07 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse
US20110177231A1 (en) * 2010-01-16 2011-07-21 Alexander Grinberg Nano-, Micro-, Macro- Encapsulation And Release Of Materials
WO2011101866A2 (en) * 2010-02-17 2011-08-25 Sun Pharma Advanced Research Company Ltd., A method of treating a disease condition susceptible to baclofen therapy
EP2415460A1 (de) * 2010-08-03 2012-02-08 ratiopharm GmbH Orale Darreichungsform von Pregabalin
GB201102148D0 (en) 2011-02-08 2011-03-23 Ucl Business Plc Layered bodies, compositions containing them and processes for producing them
WO2013009186A1 (en) * 2011-07-14 2013-01-17 APET Holding B.V. Nicotinamide compositions and the therapeutic use thereof
AU2013290875A1 (en) 2012-07-16 2015-02-05 APET Holding B.V. Gastro-retentive drug delivery system
CN104968333B (zh) 2012-11-30 2018-07-10 阿库拉制药公司 活性药物成分的自调节释放
US8859005B2 (en) 2012-12-03 2014-10-14 Intercontinental Great Brands Llc Enteric delivery of functional ingredients suitable for hot comestible applications
KR102241487B1 (ko) 2013-02-20 2021-04-16 주식회사 종근당 제어방출 펠릿으로 된 약제학적 조성물
JP2016533864A (ja) * 2013-10-22 2016-11-04 キャプソ・ヴィジョン・インコーポレーテッド マルチ密度相を有するカプセル装置に用いられるシステム及び方法
JP6510628B2 (ja) 2014-03-26 2019-05-15 サン・ファーマ・アドバンスト・リサーチ・カンパニー・リミテッド 乱用防止即時放出性被覆リザーバ固体剤形
US20170266112A1 (en) 2014-06-11 2017-09-21 Massachusetts Institute Of Technology Residence structures and related methods
MX2016016406A (es) 2014-06-11 2017-10-12 Massachusetts Inst Technology Estructuras de permanencia, y métodos relacionados.
WO2017040607A1 (en) 2015-08-31 2017-03-09 Acura Pharmaceuticals, Inc. Methods and compositions for self-regulated release of active pharmaceutical ingredient
AU2016342374B2 (en) 2015-10-23 2022-08-04 Nortiva Bio, Inc. Gastric residence systems for sustained release of therapeutic agents and methods of use thereof
KR102796240B1 (ko) 2015-12-08 2025-04-16 린드라 테라퓨틱스 인코퍼레이티드 위 체류 시스템을 위한 기하 구성형태
US12109305B2 (en) 2016-05-27 2024-10-08 Lyndra Therapeutics, Inc. Materials architecture for gastric residence systems
EP3518902A4 (en) 2016-09-30 2020-07-08 Lyndra, Inc. GASTRIC RESIDENCE SYSTEMS FOR LONG-TERM ADMINISTRATION OF ADAMANTANE CLASS MEDICINES
US11534404B2 (en) * 2016-10-06 2022-12-27 Sucampo Ag Multilayer beads for pharmaceutical use
TWI811221B (zh) 2017-06-09 2023-08-11 美商萊恩卓治療公司 具有釋放速率調節膜之胃的滯留系統
WO2019025869A1 (en) * 2017-07-31 2019-02-07 Teva Pharmaceutical Industries Limited GALENIC FORMS WITH CONTROLLED RELEASE MANUFACTURED IN ADDITIVE MANNER
AU2018388577B2 (en) 2017-12-18 2024-06-06 Tris Pharma, Inc. Modified release drug powder composition comprising gastro-retentive raft forming systems having trigger pulse drug release
US12514818B2 (en) 2017-12-18 2026-01-06 Tris Pharma, Inc. Pharmaceutical compositions comprising a floating interpenetrating polymer network forming system
US11337920B2 (en) 2017-12-18 2022-05-24 Tris Pharma, Inc. Pharmaceutical composition comprising GHB gastro-retentive raft forming systems having trigger pulse drug release
US11666546B2 (en) 2017-12-18 2023-06-06 Tris Pharma, Inc GHB pharmaceutical compositions comprising a floating interpenetrating polymer network forming system
JP7000148B2 (ja) * 2017-12-27 2022-01-19 日本化薬株式会社 ダサチニブを有効成分とする医薬組成物
US20210046011A1 (en) 2019-08-12 2021-02-18 Massachusetts Institute Of Technology Articles and methods for administration of therapeutic agents
TWI763036B (zh) * 2020-09-14 2022-05-01 王子賓 可膨脹微膠囊
MX2023010744A (es) 2021-03-15 2023-11-28 Epitomee Medical Ltd Dispositivos expandibles para la administracion de agentes activos a tejidos.
KR20250112750A (ko) 2022-09-21 2025-07-24 이피토미 메디칼 엘티디 제어 가능하게 붕해될 수 있는 자체-확장가능한 섭취형 디바이스
NL2033549B1 (en) * 2022-11-17 2024-05-28 Taiwan Mercury Medical Corp Metformin tablet for relieving pain and reducing inflammation and manufacturing method thereof
CN121358468A (zh) * 2023-05-03 2026-01-16 黑暗峡谷实验室有限责任公司 用于肠道清洁产品中的固体形式的盐的漂浮药物递送系统
DK202430306A1 (en) * 2024-06-10 2025-12-19 Merdury Biopharmaceutical Corp Oral peptide drug structure and manufacturing method thereof
WO2026105113A1 (en) 2024-11-18 2026-05-21 Epitomee Medical Ltd. Deployable devices for delivery of active agents to intestinal tissue

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5512411B2 (cg-RX-API-DMAC7.html) * 1974-03-12 1980-04-02
JPS5134879A (en) * 1974-09-19 1976-03-24 Eisai Co Ltd Bishochukuryushinoseizoho
US5002772A (en) * 1988-05-31 1991-03-26 Pfizer Inc. Gastric retention system for controlled drug release
NZ233403A (en) * 1989-04-28 1992-09-25 Mcneil Ppc Inc Simulated capsule-like medicament
JPH03101615A (ja) * 1989-09-14 1991-04-26 Sumitomo Pharmaceut Co Ltd 胃内滞留型持続性製剤
IT1246382B (it) * 1990-04-17 1994-11-18 Eurand Int Metodo per la cessione mirata e controllata di farmaci nell'intestino e particolarmente nel colon
US5314696A (en) * 1991-06-27 1994-05-24 Paulos Manley A Methods for making and administering a blinded oral dosage form and blinded oral dosage form therefor
CZ295502B6 (cs) * 1997-03-26 2005-08-17 Janssen Pharmaceutica N. V. Antifungální peleta, způsob její přípravy a farmaceutická dávková forma s obsahem těchto pelet
SE9702533D0 (sv) * 1997-07-01 1997-07-01 Astra Ab New oral formulation
US5895663A (en) * 1997-07-31 1999-04-20 L. Perrigo Company Pseudoephedrine hydrochloride extended-release tablets
US6050796A (en) 1998-05-18 2000-04-18 General Motors Corporation Vane pump
AU2001232020A1 (en) 2000-02-09 2001-08-20 West Pharmaceutical Services Drug Delivery And Clinical Research Centre Limited Floating drug delivery composition
JP2002370970A (ja) * 2001-06-12 2002-12-24 Sanwa Kagaku Kenkyusho Co Ltd 胃内浮遊型固形製剤及びその製造方法
JP4426286B2 (ja) * 2001-07-10 2010-03-03 テバ ファーマシューティカル インダストリーズ リミティド 0次、0次−二相性、上昇型又は下降型薬物放出のための薬物送達システム
US7763663B2 (en) * 2001-12-19 2010-07-27 University Of Massachusetts Polysaccharide-containing block copolymer particles and uses thereof
EP1574534A1 (en) * 2004-03-11 2005-09-14 Rohm And Haas Company Polymer carriers and process

Also Published As

Publication number Publication date
AU2007323018B2 (en) 2011-02-03
RU2009112396A (ru) 2010-10-20
NO20090807A (no) 2009-06-04
US20100015224A1 (en) 2010-01-21
WO2008062440A3 (en) 2008-07-31
AR062644A1 (es) 2008-11-19
CN101511346B (zh) 2012-07-04
CL2007002562A1 (es) 2008-02-08
IL197121A0 (en) 2009-11-18
EP2068844A2 (en) 2009-06-17
CA2661172A1 (en) 2008-05-29
CN101511346A (zh) 2009-08-19
JP2010502591A (ja) 2010-01-28
RU2420268C2 (ru) 2011-06-10
EP2068844A4 (en) 2013-01-23
ZA200901162B (en) 2010-06-30
BRPI0716481A2 (pt) 2014-03-18
MX2009002371A (es) 2009-03-12
WO2008062440A2 (en) 2008-05-29
US8277843B2 (en) 2012-10-02
AU2007323018A1 (en) 2008-05-29

Similar Documents

Publication Publication Date Title
US8277843B2 (en) Programmable buoyant delivery technology
CN1988891B (zh) 包衣片制剂和方法
ES2203885T3 (es) Formulacion de matriz de liberacion modificada de cefaclor y cefalexina.
ES2273790T3 (es) Composicion farmaceutica de liberacion sostenida.
US20060045865A1 (en) Controlled regional oral delivery
US20080286344A1 (en) Solid form
JPH07223970A (ja) 消化管内適所放出製剤
US20100233253A1 (en) Extended release gastro-retentive oral drug delivery system for valsartan
JP2015098477A (ja) 弱塩基性薬物を含む組成物及び徐放性剤形
TWI483748B (zh) 含有氫嗎啡酮(hydromorphone)和納洛酮(naloxone)之藥學組成物
KR20110097829A (ko) 낮은 pH에서 불량한 수용해도를 갖는 이온화가능한 활성제의 제어 방출을 위한 고체 조성물, 및 그의 사용 방법
EP4249055A2 (en) Tofacitinib oral sustained release dosage forms
WO2018108152A1 (zh) 一种奥拉帕尼口服缓控释药物组合物及其用途
JP2013519726A (ja) バクロフェン療法に感受性の病状の治療方法
KR20080048461A (ko) 위장체류 제제 및 이의 제조 방법
AU2013229990A1 (en) Controlled-release solid dosage forms of mesalamine
WO2012020301A2 (en) Oral controlled release pharmaceutical compositions of blonanserin
US20170027863A1 (en) Oral controlled release pharmaceutical compositions of bepotastine
JP2005132803A (ja) 胃内滞留固形剤
KR20090119986A (ko) 시간 특이적 지연성/맥동성 방출 투약 형태
KR20180024505A (ko) 개선된 생체이용률을 갖는 페노피브릭산 제제
WO2009027786A2 (en) Matrix dosage forms of varenicline
JPH0791184B2 (ja) 放出制御型製剤およびその製法
EP3796908B1 (en) Controlled release propiverine formulations
CN100536838C (zh) 一种盐酸坦洛新控释片制剂及其制备方法

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20090403

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20110107

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20130125

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20130617

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20130125

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I